2 recruiting, 1 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Hummingbird Bioscience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors ENV-501 - Melanoma (Skin), Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 180 | 2025-12-17 | 2026-03-02 |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers HMBD-001, Docetaxel, Cetuximab - Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 398 | 2024-02-05 | 2026-05-27 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
Carcinoma, Non-Small-Cell Lung (3) · Melanoma (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fibromatosis, Gingival, 2 (1) · Lethal Congenital Contracture Syndrome 2 (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Cetuximab (1) · Docetaxel (1) · enzalutamide (1)
Australia (2) · Moldova (1) · Singapore (1) · South Korea (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Johann de Bono, Prof (1) · Kevin Heller (1)